NextBio

Help
Description: Dutasteride belongs to a class of drugs called 5-alpha-reductase inhibitors, which block the action of the 5-alpha-reductase enzymes that convert testosterone into dihydrotestosterone (DHT). Finasteride also belongs to this group. Dutasteride inhibits both isoforms of 5-alpha reductase, while finasteride inhibits only one. But a clinical study done by GlaxoSmithKline, the EPICS trial, did not find dutasteride to be more effective than finasteride in treating BPH. [Wikipedia]
Drug Type: Small Molecule; Approved; Investigational
Pharmacology: Dutasteride is a synthetic 4-azasteroid compound that is a selective inhibitor of both the type 1 and type 2 isoforms of steroid 5 alpha-reductase (5AR), an intracellular enzyme that converts testosterone to 5 alpha-dihydrotestosterone (DHT). Dutasteride is indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate gland.
Mechanism of Action: Dutasteride inhibits the conversion of testosterone to 5 alpha-dihydrotestosterone (DHT). DHT is the androgen primarily responsible for the initial development and subsequent enlargement of the prostate gland. Testosterone is converted to DHT by the enzyme 5 alpha-reductase, which exists as 2 isoforms, type 1 and type 2. The type 2 isoenzyme is primarily active in the reproductive tissues while the type 1 isoenzyme is also responsible for testosterone conversion in the skin and liver. Dutasteride is a competitive and specific inhibitor of both type 1 and type 2 5 alpha-reductase isoenzymes, with which it forms a stable enzyme complex. Dissociation from this complex has been evaluated under in vitro and in vivo conditions and is extremely slow. Dutasteride does not bind to the human androgen receptor.
Indication: For the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate gland.
Half Life: 5 weeks
View Complete Description




Individual Studies
  • Drug target sets for approved compounds

    Homo sapiens Homo sapiens | Therapeutic   Therapeutic

    The DrugBank database is a unique bioinformatics and cheminformatics resource that combines detailed drug (i.e. chemical, pharmacological and pharmaceutical) data with comprehensive drug target (i.e. sequence, structure, and pathway) information.

    Authors: David S Wishart, Craig Knox, An Chi Guo et al.

    Organization: Department of Computing Science, Univers…

View All Individual Studies

Thought leaders and organizations working on research involving dutasteride.

  • Claus G Roehrborn
  • Paul Siami
  • Francesco Montorsi
  • Stephanie T Page
  • Timothy Wilson
  • GlaxoSmithKline
  • University of Washington
  • Beth Israel Deaconess Medical Center
  • Siami, Paul F., M.D.
  • Northwestern University
  • Washington University School of Medicine
  • UT Southwestern Medical Center
  • University of Washington
  • Barzilai Medical Center
  • Fred Hutchinson Cancer Research Center

Clinical Trials | 120 trials

Help for Clinical Trials View All

News | 14 stories

Help for News View All

Community

Help for Community
  • No NextBio users were found for “dutasteride”.
    Complete your user profile with your interests, if you want others to find you within the NextBio community.

  • No NextBio groups were found for “dutasteride”.
    Be the first to start a group and share your interests with others within the NextBio community.